{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T07:31:07.387883+00:00","company":{"ticker":"KRYS","cik":1711279,"company_name":"Krystal Biotech, Inc."},"pagination":{"limit":100,"returned":2,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"9b7fcf238ec3c422c3b9ad1f1acb2c3a68b8cc9d","cik":1711279,"ticker":"KRYS","company_name":"Krystal Biotech, Inc.","filed_at":"2026-05-04T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter ending March 31, 2026","report_date":"2026-05-04","result_type":"reported_results","revenue_text":"$116.4 million"},"claim":"Krystal Biotech, Inc. reported first quarter ending March 31, 2026 results: revenue $116.4 million.","evidence_excerpt":"Krystal Biotech Announces First Quarter 2026 Financial and Operating Results $116.4 million in 1Q VYJUVEK global revenue and $846.7 million since launch","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001711279-26-000044","anchor_url":"https://secwatch.observer/filing/0001711279-26-000044#claim-9b7fcf238ec3c422c3b9ad1f1acb2c3a68b8cc9d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000044/0001711279-26-000044-index.htm"},{"fact_type":"earnings_release","fact_key":"7ccffa5710ddcf9c63b7f9875a94a66bf67f4634","cik":1711279,"ticker":"KRYS","company_name":"Krystal Biotech, Inc.","filed_at":"2024-05-06T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first quarter ending March 31, 2024","report_date":"2024-05-06","result_type":"reported_results","revenue_text":"$45.3 million"},"claim":"Krystal Biotech, Inc. reported the first quarter ending March 31, 2024 results: revenue $45.3 million.","evidence_excerpt":"The Company recorded $45.3 million in VYJUVEK net product revenue for the first quarter of 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001711279-24-000018","anchor_url":"https://secwatch.observer/filing/0001711279-24-000018#claim-7ccffa5710ddcf9c63b7f9875a94a66bf67f4634","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127924000018/0001711279-24-000018-index.htm"}]}